Guardant Health's Next Big Challenge: Reimbursement The Shield diagnostic candidate is likely to earn FDA approval, but might struggle to earn favorable CMS reimbursement. That could complicate launch -- and Guardant Health's $GH existence. $EXAS www.living.tech/articles/gua...

Guardant Health's Next Big Challenge: Reimbursement | Solt DB

Shield is likely to become the second blood test approved to screen for colon cancer, but reimbursement coverage might disappoint investors and complicate commercial launch.